Kremers Urban reaches settlement agreement with ALZA over Concerta patent litigation

Download PDF Copy

Sep 14 2011

Kremers Urban Pharmaceuticals Inc. is pleased to announce that it has reached a settlement dismissing all pending litigation arising from its Abbreviated New Drug Application (ANDA) to market an extended release methylphenidate hydrochloride product, for which Concerta® is the reference listed drug product. The ANDA is currently under review with FDA.

The settlement includes a patent license and covenant, under existing ALZA Corporation patents under which Kremers Urban may commercially launch its methylphenidate ANDA product on July 1, 2012, or earlier under certain circumstances, pending FDA approval.

Source:

Kremers Urban Pharmaceuticals Inc.

Posted in: Medical Patent News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Global cancer cases and deaths expected to soar by 2050 despite advances in treatment

Off-label drug helps one boy with autism speak, parents say. But experts want more data.

Largest study of African American brain tissue reveals key Alzheimer gene activity

Scientists test whether chaya leaves can lower blood sugar in diabetes

University of Maine team develops sustainable method to cut drug production costs

Mass General Brigham study shows US obesity could jump from 40% to 70%

‘Sick to my stomach’: Trump distorts facts on autism, tylenol, and vaccines, scientists say

Mentavi study validates first fully digital diagnostic pathway for adult ADHD

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.